Actively Recruiting
Evaluating UX-GIP001 Cell Therapy for Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy A Phase I Safety and Preliminary Efficacy Study
Led by Shanghai UniXell Biotechnology Co., Ltd · Updated on 2026-11-04
12
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating UX-GIP001, a new cell therapy made from human GABAergic interneuron progenitor cells, for adults with drug-resistant unilateral mesial temporal lobe epilepsy MTLE. This phase I, open-label, single-arm study aims to assess the safety, tolerability, and early signs of effectiveness of this treatment by comparing seizure frequency and safety before and after the transplant. Participants will receive one of two planned dose levels of UX-GIP001 through stereotactic neurosurgery. This procedure is supported by immunosuppressive therapy before and after the transplant. The study includes a baseline period to confirm eligibility and a 24-month follow-up phase where researchers will conduct regular safety assessments, perform neuroimaging, and monitor seizure activity via patient diaries. Quality of life, cognitive function, and mood will also be evaluated throughout the study. During the 24-month follow-up, participants will have ongoing evaluations including seizure frequency tracking, safety monitoring of adverse events related to surgery, transplanted cells, and immunosuppressive therapy. Researchers will also assess responder rates and seizure-free status compared to baseline. The primary outcome measures focus on adverse events within six months post-treatment, while secondary outcomes extend to two years. Participants are expected to comply with diary entries and attend regular visits for these assessments.
CONDITIONS
Brief Title
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Research Team
X
Xianwei Zhi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here